Introduction
This is the decade of eosinophilic esophagitis. What was originally a case reportable disease ten years ago is now one that is appearing in numerous gastrointestinal and allergy journals on a regular basis and is a headline topic at national and international meetings in both of these fields. Recognition of this disease for the gastroenterologist has become paramount because of its differentiation from gastroesophageal reflux not only from an etiologic but especially from a treatment point of view. Furthermore, as study of eosinophilic esophagitis continues, we are starting to recognize common clinical scenarios that we might normally attribute to other disease entities as potentially typical presentations of eosinophilic esophagitis. Some of the current literature on this interesting entity will be reviewed.
Eosinophilic esophagitis: pathogenesis
One of the fascinating issues in eosinophilic esophagitis is understanding the causes of eosinophilic infiltration of the esophagus, an organ normally devoid of eosinophils as compared with blood and the remainder of the gastrointestinal tract. Studies previously have carefully outlined an allergic type pathway in both animal models and in humans. Specifically, analysis of biopsy specimens in eosinophilic esophagitis demonstrates increased T-cells, mast cells, IL-5 and tumor necrosis factor-a, which stimulate eotaxin, all central to the allergic reaction [1] . Biopsy specimens also demonstrate increased numbers of CD3, CD8 and CD1a antigen-presenting cells, also compatible with allergic etiology [2] . Recent work by Straumann and colleagues [3 ] goes further by characterizing some of the differences between the populations of eosinophils normally found in blood and gut in contrast to those abnormally found in the esophagus in patients with eosinophilic esophagitis. It is specifically demonstrated that esophageal eosinophils in eosinophilic esophagitis are more likely to be in an activated form characterized by greater levels of activation markers CD25, IL-4, and IL-5 when compared to duodenal tissue from both eosinophilic esophagitis patients and normal controls. Interestingly, IL-13 (a key cytokine in the pathogenesis of allergic disorders), was elevated in both esophageal and duodenal biopsies in patients with eosinophilic esophagitis despite a lack of inflammation in the latter site. Moreover, patients with eosinophilic esophagitis had increased IL-5 and IL-13 expression in blood eosinophils, suggesting a systemic preactivation in response to allergen exposure before esophageal infiltration occurs. These important data give credence to a distinct population of blood-borne and presumably marrow-derived eosinophils found in the esophagus of patients with eosinophilic esophagitis. How and why this particular sub-population of eosinophils homes to the esophagus more selectively is yet to be determined.
Fortunately, critical recent data from the laboratory of Dr Rothenberg [4 ] give further insight into this question. They suggest that there might be early antigen priming that in turn predisposes to the development of eosinophilic esophagitis later in life after further and perhaps different antigen exposures. In their elegant mouse model of eosinophilic esophagitis, mice injected epicutaneously with either Aspergillus fumigatus antigen (known to induce eosinophilic esophagitis in a similar model) or antigen ovalbumin alone develop atopic dermatitis but do not develop eosinophilic esophagitis. These mice were also shown to have a marked activation of bone marrow eosinophil proliferation through an IL-5 mechanism. In contrast, epicutaneoulsy injected mice then exposed to intranasal A. fumigatus or ovalbumin do develop eosinophilic esophagitis as well as lung inflammation. These are exciting findings which suggest the occurrence of a two or perhaps multi-step process in the development of eosinophilic esophagitis first involving a priming cutaneous allergic response, a systemic activation of bone marrow eosinophils, which then home to the esophagus and lung in the presence of a later respiratory (or oral) allergen exposure. For such a new disease to be dissected out so elegantly so quickly speaks volumes for the work of this and other laboratories.
Eosinophilic esophagitis: presentation and diagnosis
As our appreciation of the increasing prevalence of eosinophilic esophagitis continues, it would make sense that we would see it more commonly in specific clinical presentations. In a study by Desai et al. [5 ] , from Dr Furuta's group, eosinophilic esophagitis was noted to be the most common cause of food impaction in a primary gastroenterology practice. Specifically, over a 3-year period, 17 of 31 patients presenting with food impaction to a community-based hospital had eosinophilic esophagitis. Even more striking was the finding of an age difference of at least 25 years when separating younger patients into a group meeting histologic criteria for eosinophilic esophagitis. This paper not only underscores the commonality of eosinophilic esophagitis as a cause of the extreme of dysphagia -a food impaction -but also emphasizes that in a young adult, eosinophilic esophagitis is the most likely cause of such a presentation. Interestingly, this group has also reported that eosinophilic esophagitis may have the identical appearance to a Schatzki ring [6] .
Another emerging theme in eosinophilic esophagitis is the role of family history. Most studies have discussed a high prevalence of allergy in family members in general and, not surprisingly, several investigators have noted anecdotally more than one family member with eosinophilic esophagitis.
A recent case series formally discusses three brothers between the ages of 34 and 44 years all with eosinophilic esophagitis [7] . Whether this provides a purely genetic basis or one combined with common environmental exposures is unclear at this time.
In adults, the first test for evaluation for dysphagia by many gastroenterorlogists is barium esophagography. A study from a leading gastrointestinal radiology group outlines several of the radiographic findings in eosinophilic esophagitis [8] . Although findings are similar to those found endoscopically (e.g. rings and strictures predominantly), recognition of the characteristics of these patterns from a radiographic view is important. This study also points out an interesting aspect of diagnosis not emphasized quite as well in the endoscopic literature, which is that these rings or strictures are of varying length and diameter and can be found in any location throughout the esophagus. Those in the distal esophagus may closely mimic a reflux induced stricture, making differentiation from reflux often difficult. Unfortunately, as superb gastrointestinal radiologists become a dying breed, these results may not be as important in the future, but in the ideal medical world a good barium swallow in a patient with dysphagia will still remain an important tool in the evaluation of eosinophilic esophagitis. One further concern with barium esophagography is that the most subtle but prevalent findings of eosinophilic esophagitis, specifically mucosal furrowing [9] , 'white specks' [10] and easy tearing of the esophageal mucosa [11] , will not be seen on routine esophagography.
Eosinophilic esophagitis: treatment and natural history
Until this point, most studies on treatment and follow-up of eosinophilic esophagitis have been of the order of months to a few years in small populations of patients. Short-term trials have mostly advocated the use of inhaled steroids (fluticasone) and food avoidance therapies but long-term trials are desperately needed to elucidate the time course needed for these treatments. This is particularly important in light of one long-term followup study in adults demonstrating little improvement and commonly progression of disease [12] . Dr Liacouras and colleagues [13 ], a group with extensive experience in treating children with this disorder, recently reported on a 10-year history in 381 children with eosinophilic esophagitis. Their comprehensive study underscored several of the characteristics of patients with eosinophilic esophagitis discussed in much smaller studies. These include the high prevalence (53%) of other allergic disorders in these patients such as asthma, allergic rhinitis or eczema; the patchy distribution of eosinophils in some patients mandating multiple levels of biopsy during endoscopy; the variety of endoscopic findings, including normal esophageal appearance; and, finally, the panoply of symptoms in children with eosinophilic esophagitis, including nausea, vomiting, heartburn or epigastric pain in contrast to dysphagia found much more commonly in older children and adults. This study gives even more valuable insight to treatment. Specifically, they document the effective yet transient, of the order of months, effect of oral or inhaled steroids on symptoms and reduction of esophageal eosinophilia. In contrast, the use of rigid food avoidance based on skin prick and patch testing, and more drastically, the use of an amino-acid based elemental formula, proved a far more durable therapy as regards reduction of symptoms and normalization of esophageal biopsy. As expected, however, reintroduction of problem foods, resulted in clinical and tissue relapse in most patients. This landmark study underscored the difficulties we have at present, and will have for some time, in the treatment of eosinophilic esophagitis, namely the transient but better tolerated nature of pharmacologic therapy in contrast to the more effective and durable therapy of food elimination for which it is difficult to gain patient acceptance for 10 years let alone a lifetime.
One of the concerns in fully embracing dietary restriction as the dominant therapy for eosinophilic esophagitis is in the reliability and type of testing that should be used to identify these allergens. For example, skin prick testing alone when used to dictate diet therapy may not be reliable for predicting response in eosinophilic esophagitis for a majority of patients. In one study, Dr Spergel and colleagues [14 ] define their patients' diet restrictions based on a positive food identification on either atopy patch testing or skin prick testing. Those patients with greater than 10 foods identified are put on elemental feedings. After 6 weeks of therapy, 112 and 19 of the 146 patients had either complete or partial response, respectively. Although impressive, several details must be noted. Patients had an average of 3.2 AE 4.3 positive foods, with the most common foods identified as soy, wheat, milk, rice, chicken, beef and potato (i.e., very common foods and difficult to avoid). Forty patients also eventually required use of an elemental diet to attain or sustain remission. Finally, no allergies were identified in five patients, and in two patients avoidance of milk resulted in response despite negative testing. This article underscores the importance of comprehensive skin testing in patients with eosinophilic esophagitis as primary therapy but also highlights the existing imprecision and inconvenience of this strategy as well. Whether we will be able to use these or other tests to approach uniform reliability in tailoring diet therapy or make it more tolerable to eosinophilic esophagitis patients has yet to be determined.
Conclusion
Eosinophilic esophagitis is an evolving disease. Recent data continue to support a key role for allergy in its pathogenesis, though gastroesophageal reflux disease as a potential co-factor, particularly in adults, needs further attention. Clues emerge on the typical presentation of this disease. Intermittent dysphagia in a young adult over many years, particularly with an episode of food impaction, should alert the gastroenterologist to the possibility of eosinophilic esophagitis. This becomes especially likely in the face of a personal and family history of other allergic disorders, let alone another family member with eosinophilic esophagitis. Treatment is still focused on oral topical or systemic steroids and food avoidance but while the former lacks established long-term safety, the latter lacks long-term acceptance. One can be sure rapid advances in treatment and in understanding eosinophilic esophagitis in general will be made over the next decade as interest continues to soar.
